CONSIDERATION OF DRAFT AND PROPOSED DRAFT MAXIMUM RESIDUE LIMITS FOR VETERINARY DRUGS RETAINED AT STEPS 7 AND 4 (Agenda Item 8)[35]

Revision of Codex Maximum Residue Limits

CARAZOLOL

93. The Committee noted that all MRLs for carazolol had been returned to Step 7 by the 22nd Session of the Commission due to concerns that the concentration of residues at the injection site might exceed the ADI[36]. Recognizing that high level residues at the injection site could pose health risks, the Committee agreed to retain all draft MRLs at Step 7 (see Appendix IV) and to request JECFA to review this issue based on the principles outlined in the paper contained in CL 1998/4-RVDF on Guidelines on Residues at Injection Sites (also see paras. 111-115).

CEFTIOFUR

94. The Committee noted that the MRLs for ceftiofur had been retained at Step 7 by the 10^th CCRVDF pending the reevaluation of the compound by the 48^th JECFA[37]. The Committee agreed to advance all draft MRLs, as amended by JECFA, to Step 8 (see Appendix II).

CLENBUTEROL

95. The Committee noted that no new information had become available on this substance since the 10^th CCRVDF[38]. Due to concerns about residues of clenbuterol arising from misuses, the Committee decided to retain all proposed draft MRLs at Step 4 (see Appendix VI).

Revision of Codex Maximum Residue Limits

MOXIDECTIN[39]

96. The Committee noted that the 50th JECFA converted the temporary MRLs for deer tissues to full MRLs maintaining the same levels. As these temporary MRLs had been adopted by the Commission in 1997[40], the Committee agreed to advance the full MRLs for deer tissues to Step 5/8, with a recommendation to omit Steps 6 and 7 (see Appendix III).